Novartis stock falls 1.46 percent after Abogen deal announcement
Published on 10/03/2026 at 23:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis stock (ISIN CH0012005267) was last at CHF 116.34 on SIX on October 2, 2026, down 1.46 percent from the previous session. The move came as the Swiss drugmaker announced a potential USD 7.8 billion licensing agreement with Abogen Biosciences, putting pipeline expansion back at the center of the investment case.
Abogen deal reaches USD 7.8 billion
According to CNBC on October 2, 2026, Novartis will pay USD 575 million upfront for global rights to Abogen's messenger RNA therapy. A further USD 7.2 billion is tied to development and regulatory milestones, taking the potential agreement value to USD 7.8 billion.
The asset is an early-stage experimental treatment for autoimmune disease, while Novartis also receives an exclusive option to license additional programs developed on Abogen's RNA platform. For investors, the payment structure matters: the upfront amount represents 7.4 percent of the agreement's maximum value, leaving most of the headline figure dependent on future development progress.
Stock stays below its yearly high
Novartis' SIX share price stood 12.3 percent below its 52-week high of CHF 132.68 on October 2, 2026, while the 52-week low was CHF 97.05. The stock remained up 7.72 percent year to date, showing that the recent weakness has not erased its annual gain.
The same session's trading range was CHF 116.20 to CHF 118.64, with the reference price near the day's low. Market capitalization was CHF 221.1 billion as of October 2, 2026, giving the pipeline transaction a maximum value equal to 3.5 percent of the company's equity value.
Results set the next checkpoint
Novartis lists its second quarter 2026 results on July 21, 2026, the latest reporting milestone shown on its investor page. The Abogen transaction therefore adds a business-development signal between reporting dates, but its financial contribution depends on clinical, regulatory and commercial execution.
That distinction separates the immediate headline from the longer valuation question. Novartis has secured access to an RNA platform and a lead asset, while the largest cash commitments remain conditional on milestones rather than due at signing.
Novartis stock trades at CHF 116.34
Novartis stock was last at CHF 116.34 on SIX on October 2, 2026 at 5:30 p.m. CEST, down 1.46 percent on the session. The CHF 221.1 billion market capitalization and 12.3 percent gap to the 52-week high frame the Abogen agreement as a pipeline investment inside a large established pharmaceutical company.
Novartis stock key data
- Company: Novartis AG
- ISIN: CH0012005267
- Ticker: NOVN
- Trading venue: SIX Swiss Exchange
- Price (as of October 2, 2026, 5:30 p.m. CEST): CHF 116.34
- Market capitalization: CHF 221.1 billion (as of October 2, 2026)
- 52-week range: CHF 97.05-132.68 (as of October 2, 2026)
- Sector / Industry: Pharmaceuticals
